Long-term outcomes with HLX01 (HanliKang(®)), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
HLX01(韩利康®,一种利妥昔单抗生物类似药)治疗既往未接受治疗的弥漫性大B细胞淋巴瘤患者的长期疗效:3期HLX01-NHL03研究的5年随访结果
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-11876-9
Qin, Yan; Song, Yongping; Wang, Dong; Bai, Ou; Feng, Jifeng; Sun, Xiuhua; Qiu, Lihua; Yang, Jianmin; Yang, Yu; Wang, Zhao; Hu, Jianda; Wang, Huaqing; Su, Hang; Jin, Zhengming; Qian, Wenbin; Jin, Chuan; Zhang, Mingzhi; Yu, Ding; Liu, Li; Chen, Guoan; Li, Yarong; Sun, Tao; Jin, Jie; Bao, Huizheng; Du, Xin; Zhou, Hui; Fu, Gan; Shi, Yuankai